UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
      D.C. 20549
 
      
FORM 8-K
      
CURRENT REPORT
      
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of
      1934
        
Date of Report (Date of earliest event reported): November 15, 2007

        
      
  
    
      
PFIZER INC.
(Exact
      name of registrant as specified in its charter)
  
    
      
   
  
    
      
DELAWARE
(State or other jurisdiction of
      incorporation)
    
      
1-3619
(Commission File Number)
    
      
13-5315170
(I.R.S. Employer Identification
      No.)
  
    
      
       
  
    
      
235 East 42nd Street, New York, New
      York   10017
     (Address of
      principal executive offices)   (zip code)
      
(212) 573-2323
(Registrant's telephone
  number)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the obligation of the registrant
under any of the following provisions:
[ ]  Written communication
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]  Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[ ]  Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]  Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Item 8.01. Other
Events
Exhibit 100 to this Current Report on Form 8-K
  contains documents formatted in XBRL (eXtensible Business Reporting Language)
  with information from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter
  ended September 30, 2007, filed with the Securities and Exchange Commission
  (SEC) on November 5, 2007. The information formatted in XBRL includes the (i)
  Condensed Consolidated Statements of Income for the three months and nine months
  ended September 30, 2007, and October 1, 2006,  (ii) Condensed Consolidated
  Balance Sheets as of September 30, 2007, and at December 31, 2006, and (iii)
  Condensed Consolidated Statements of Cash Flows for the nine months ended September
  30, 2007 and October 1, 2006.
Users of this data are advised pursuant to Rule
401 of Regulation S-T that the financial information contained in the
XBRL-Related Documents is unaudited and these are not the official financial
statements of Pfizer Inc. as filed with the SEC. The purpose of furnishing these
XBRL formatted documents is solely for the purpose of participation in the SEC's
voluntary XBRL pilot program to test the related format and technology and, as a
result, investors should continue to rely on the official filed version of the
furnished documents and not rely on the information in this Current Report on
Form 8-K, including Exhibit 100, in making investment decisions.
In accordance with Rule 402 of
Regulation S-T, the information in this Current Report on Form 8-K, including
Exhibit 100, shall not be deemed to be "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
otherwise subject to the liability of that section, and shall not be
incorporated by reference into any registration statement or other document
filed under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and
Exhibits.


  
    
      
(d) 
    
      
Exhibits
  
     
     
  
    
    
      
The following exhibits are furnished
      herewith:
  
     
     
  
    
    
      
 Exhibit
      Number
    
      
Exhibit
      Description 
  
    
    
      
    
    
      
 
  
    
    
      
100
    
      
The following financial statements from
        Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended September
        30, 2007, filed on November 5, 2007, formatted in XBRL (extensible Business
        Reporting Language): (i) the Condensed Consolidated Statements of Income
        for the three months and nine ended September 30, 2007, and October 1,
        2006, (ii) the Condensed Consolidated Balance Sheets as of September 30,
        2007, and December 31, 2006, and (iii) the Condensed Consolidated Statements
        of Cash Flows for the nine months ended September 30, 2007 and October
        1, 2006.
    



  
    
      
SIGNATURE
  
       
     
     
  
    Under the requirements of the Securities
      Exchange Act of 1934, the registrant has caused this report to be signed
      on its behalf by the authorized undersigned.
  
       
     
     
  
     
     
     
  
    
    
    
      
PFIZER INC.
  
     
     
       
  
     
     
    By: /s/ Margaret M.
      Foran
  
     
     
     Margaret M. Foran
  
    
    
    
  
    
    
    
      
  
    
      
Dated: November 15, 2007
    
    
    
      
Title:  Senior Vice
      President-Corporate Governance
  
     
     
    Associate General Counsel and Corporate
      Secretary
  
     
     
     
  
     
     
     




  
    
      
EXHIBIT INDEX
  
    
      
    
    
         
  
    
      
Exhibit No.
    
      
  
    
      
Description
  
    
    
  
    
      
EX-100.INS
    
      
  
    
      
XBRL Instance Document
  
    
      
  
    
  
    
      
EX-100.SCH
    
      
  
    
      
XBRL Taxonomy Extension Schema
      Document
  
    
      
  
    
  
    EX-100.SCH.1
     
    XBRL Schema Supplement Document
  
    
      
 
    
  
    
      
EX-100.CAL
    
      
  
    
      
XBRL Taxonomy Extension Calculation
      Linkbase Document
  
    
      
  
    
  
    
      
EX-100.LAB
    
      
  
    
      
XBRL Taxonomy Extension Label Linkbase
      Document
  
    
      
  
    
  
    
      
EX-100.PRE
    
      
  
    
      
XBRL Taxonomy Extension Presentation
      Linkbase Document